Abstracts
3 June 2009
Vol. 1 No. 8 (2005)
https://doi.org/10.4081/hmr.v1i8.294

Direct and indirect antitumor activity of zoledronic acid

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
240
Views
319
Downloads

Authors

M Massaia
support@pagepress.org
S Mariani
F Pantaleoni
M Muraro
S Peola
SY Hwang
B Castella
G Matta
Zoledronic acid (Zol) is the most potent aminobisphosphonate currently available to treat bone disease in cancer patients.1 Zol specifically targets the mevalonate (MVA) pathway of osteclasts precursors and mature osteoclasts. By inhibiting the farnesyl pyrophosphate (FPP) synthase, Zol prevents the generation of FPP and geranylgeranylpyrophosphate (GGPP) that are essential compounds to prenylate proteins like Ras and Rho among others.2 The accumulation of unprenylated proteins in osteoclast precursors and mature osteclasts prevents their differentiation and activation and ultimately leads to cell death by apoptosis. By acting upstream on the same pathway targeted by farnesyl transferase (FTase) and geranylgeranyltransferase (GGTase) inhibitors (FTI, GGTI), Zol can be considered as a drug impacting on farnesylation-dependent survival and differentiation pathways.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Direct and indirect antitumor activity of zoledronic acid. (2009). Hematology Meeting Reports, 1(8). https://doi.org/10.4081/hmr.v1i8.294